We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 26th:
Ternium S.A. (TX - Free Report) : This steel products manufacturer has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 2.1% over the last 60 days.
Lannett Company, Inc. : This manufacturer of generic versions of brand pharmaceutical products has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1.9% over the last 60 days.
DXC Technology Company (DXC - Free Report) : This information technology services provider has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1.1% over the last 60 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Top Ranked Value Stocks to Buy for February 26th
Here are three stocks with buy rank and strong value characteristics for investors to consider today, February 26th:
Ternium S.A. (TX - Free Report) : This steel products manufacturer has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 2.1% over the last 60 days.
Ternium S.A. Price and Consensus
Ternium S.A. price-consensus-chart | Ternium S.A. Quote
Ternium has a price-to-earnings ratio (P/E) of 6.18 compared with 11.30 for the industry. The company possesses a Value Score of A.
Ternium S.A. PE Ratio (TTM)
Ternium S.A. pe-ratio-ttm | Ternium S.A. Quote
Lannett Company, Inc. : This manufacturer of generic versions of brand pharmaceutical products has a Zacks Rank #1 (Strong Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1.9% over the last 60 days.
Lannett Co Inc Price and Consensus
Lannett Co Inc price-consensus-chart | Lannett Co Inc Quote
Lannett has a price-to-earnings ratio (P/E) of 4.43 compared with 11.30 for the industry. The company possesses a Value Scoreof A.
Lannett Co Inc PE Ratio (TTM)
Lannett Co Inc pe-ratio-ttm | Lannett Co Inc Quote
DXC Technology Company (DXC - Free Report) : This information technology services provider has a Zacks Rank #2 (Buy), and seen the Zacks Consensus Estimate for its current year earnings rising 1.1% over the last 60 days.
DXC Technology Company. Price and Consensus
DXC Technology Company. price-consensus-chart | DXC Technology Company. Quote
DXC Technology has a price-to-earnings ratio (P/E) of 8.09 compared with 13.40 for the industry. The company possesses a Value Score of A.
DXC Technology Company. PE Ratio (TTM)
DXC Technology Company. pe-ratio-ttm | DXC Technology Company. Quote
See the full list of top ranked stocks here
Learn more about the Value score and how it is calculated here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>